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The second Caucasian xeroderma pigmentosum patient
(XP42RO) belonging to complementation group F
(XP-F) is described. Mild ocular photophobia was present
from childhood, and acute skin reactions occurred upon
exposure to sunlight. Basal and squamous cell carcinomas
developed after his twenty-seventh year. In his late forties
progressive neurologic symptoms emerged, which
included intellectual decline, mild chorea and ataxia, and
marked cerebral and cerebelar atrophy. Such neurologic
abnormalities are very unusual in XP-F. Similar symp-
toms have been described in only one of 17 other XP-F
individuals. His µ5-fold reduced activity of nucleotide
excision repair in cultured cells, combined with moder-
ately affected cell survival and DNA replication after UV
exposure, are typical of XP-F. The recent cloning of the
The autosomal recessive disease xeroderma pigmentosum(XP) is clinically manifested by photosensitivity of skinand eyes and early onset of freckling and other lesionson sun-exposed skin, culminating in a high propensity toneoplasms, especially carcinomas. Progressive neurologic
degeneration occurs in some XP patients, varying from central nervous
system abnormalities to, in rare cases, additional peripheral nerve
dysmyelination characteristic of Cockayne syndrome (Cleaver and
Kraemer, 1994). The photosensitivity of XP patients is due to defective
nucleotide excision repair (NER), a process responsible for the removal
of DNA damage induced by UV and diverse chemical mutagens. NER
is a complex mechanism, requiring the correct interplay of about 30
different genes (Aboussekhra et al, 1995; Mu et al, 1995). Seven of
these, named XPA to XPG, were found to be defective in XP patients.
The XPA, XPC, and XPE proteins are probably involved in damage
recognition, whereas XPB and XPD mediate subsequent local
unwinding of the DNA helix. XPF and XPG are required for strand
cleavage at either side of the DNA lesion. In the final stages of NER,
the damaged patch is removed and replaced using enzymes from the
DNA replication machinery.
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XPF gene allowed a molecular genetic analysis of this
unusual patient. XP42RO, representing the second case
studied in this respect, turned out to be homozygous for
a point mutation in the XPF gene, causing an R788→W
substitution in the encoded protein. Surprisingly, this
mutation had also been found in one allele of the other
unrelated Caucasian XP-F case. The amount of mutated
XPF protein is strongly reduced in cells from XP42RO,
presumably due to a conformational change. Bio-
chemical, genetic, and clinical data all indicate the
presence of considerable residual repair activity, strongly
suggesting that the R788W mutation is leaky. Key words:
ERCC1/nucleotide excision repair/skin cancer. J Invest
Dermatol 110:832–836, 1998
Most NER defective XP patients are affected in XPA or XPC,
followed by XPD. XPF and XPG defects are less frequent and only
rare cases with XP-B and XP-E have been described. A patient with a
mutated XPF gene, first identified in 1979 by genetic complementation
analysis (Arase et al, 1979), showed relatively mild cutaneous symptoms
and no neurologic involvement. This picture is characteristic of the
XP-F patients reported later on, all from Japan (Nishigori et al, 1986;
Yamamura et al, 1989) (see Table II) except for one from Europe
(Norris et al, 1988). One exceptional Japanese case was identified
having neurologic abnormalities (Moriwaki et al, 1993). Here we
describe a European XP-F patient with multiple carcinomas and other
mild oculocutaneous symptoms, who developed marked neurodegener-
ation after his late forties. In view of this unusual clinical picture, we
conducted detailed biologic and biochemical studies of his NER
capabilities. After the recent cloning of the XPF gene (Sijbers et al,
1996a), molecular genetic analysis has also become possible. Here we
report the second XP-F patient studied in this respect. To our surprise,
we found a homozygous mutation, identical to one of the XPF alleles
of the first patient.
MATERIALS AND METHODS
Case report Patient XP42RO, aged 62 y, is one of nine siblings from
nonconsanguineous parents of Dutch origin. From about 10 y of age he
developed irregularly pigmented macules and telangiectasia on cheeks, temples,
and dorsa of hands. From his fifteenth to twenty-seventh year he worked
outdoors as a farm laborer, experiencing frequent acute sunburn reactions. Since
his thirties, nine basal or squamous cell carcinomas have been removed from
sun-exposed areas. Mild photophobia and occasional conjunctival vasoinjection
were present from childhood. At age 47, his 24 h and 72 h MED were 0.08
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and 0.04 J per cm2 of UV light, respectively, corresponding to the most sensitive
type I skin individuals.
After the age of 47, neurologic symptoms started to appear in the form of
progressive dysarthria, clumsiness, restlessness, and a mild chorea. Ataxia with
unsteady gait, dysmetria of the limbs, and saccadic dysmetria of ocular movement
are now present. Nuclear magnetic resonance showed a corresponding marked
atrophy of the cerebelum and cerebral cortex. Electroencephalogram, reflexes,
and audiogram were normal. Signs of central nerve conduction impairment
were noted in somatosensory and motor evoked potentials. Electromyography
findings suggested mild axonal polyneuropathy. Neurophysiologic testing
revealed deficiencies in attention, concentration, and recall as well as visuospatial
and constructional deficits. 1-chloro-2,4-dinitrobenzene testing (Bleumink et al,
1974) revealed a normal cell-mediated immune response. The patient is married
without offspring, due to gonadal dysplasia. The family history revealed that
sun sensitivity was also noted in the father, but without the development of
severe skin lesions and neoplasms. None of the patient’s siblings are known to
have similar neurologic or cutaneous problems.
Cell strains and culture Primary skin fibroblasts were cultured routinely in
Ham’s F10 medium supplemented with 15% fetal bovine serum and antibiotics.
Cell strains used were XP42RO (patient), 95RD28 (patient’s father), XP25RO
(XP-A), XP11BE (XP-B), XP20RO, XP21RO and XP3MA (XP-C), XP1BR
and XP2CS (XP-D), XP2RO (XP-E), XP2YO and XP126LO (XP-F), XP3BR
(XP-G), and C5RO (normal control).
DNA repair studies The UV source was a standard germicidal mercury
tube emitting UVC rays of predominantly 254 nm. NER activity was assayed
in cultured fibroblasts as unscheduled DNA synthesis (UDS), by measuring UV
induced incorporation of tritiated thymidine in autoradiograms, as described
elsewhere (Vermeulen et al, 1994a). The number of grains above the nuclei
represents the cellular repair activity. The short-term effect of UV on nucleic
acids synthesis was similarly assayed by [3H]thymidine incorporation 16 h after
irradiation (Hamel et al, 1996). A simplified assay was used for cellular survival
(Hamel et al, 1996). In short, sparsely seeded, 2 d old cultures were exposed to
graded UV doses. Three to five days after irradiation, the number of proliferating
cells was estimated by liquid scintillation counting of tritiated thymidine
incorporated during a 3 h pulse. For complementation analysis, XP cells were
fused using Sendai virus and assayed for UDS after 24–48 h, as described
(Keijzer et al, 1979).
General biochemical procedures Nucleic acids purification, restriction
enzyme digestions, gel electrophoresis, and immunoblot analysis were performed
according to standard procedures (Sambrook et al, 1989). Coupled in vitro
transcription and translation reactions using the TNT reticulocyte lysate system
were performed as described by the manufacturer (Promega, Madison, WI).
Labeled translation products were analyzed by standard sodium dodecyl sulfate-
polyacrylamide gel electrophoresis.
Mutational analysis The XPF gene was amplified in two overlapping
segments by polymerase chain reaction from cDNA prepared from total cell
RNA isolated from cultured fibroblasts using random hexamers. Products were
digested with different sets of restriction enzymes and 59 end labeled with 32P-
phosphate (Sijbers et al, 1996a). Labeled single strands were separated based on
conformation in nondenaturing polyacrylamide gels containing 5% glycerol and
run at 4°C, as described (Liu and Sommer, 1995). Amplified genomic or cDNA
fragments were directly sequenced (USB).
Microinjection XPF cDNA subcloned in a mammalian expression vector
pcDNA3 (Invitrogen, Leek, the Netherlands) was microneedle-injected into
one nucleus of XPF deficient XP126LO homopolykaryons. After a 24 h
expression period, UV-UDS was measured in the injected cells (Vermeulen
et al, 1994a).
RESULTS
DNA repair studies The overall activity of NER was assayed in
cultured skin fibroblasts as UDS, i.e., UV-induced incorporation of
tritiated thymidine was measured by autoradiography. In the patient,
NER after exposure to 10 J per m2 was reduced to 22% of normal
levels (Table I, top panel) and varied between 15% and 30% on other
occasions (not shown). NER in the cells of the father was in the
normal range (see Table I). Genetic complementation analysis was
performed to identify the gene defect. After fusion of XP42RO
fibroblasts with one or two known representatives from all seven XP
groups A through G (for strains see Materials and Methods), normal or
near-normal UDS levels were obtained in all cases except for the XP-
F strain XP126LO where UDS remained low in the heterokaryons
Table I. Correction of NER activity in XP42RO
Repair
Sample tested Grains per nucleusa activityb
Standard NER assay
XP42RO (patient) 12.9 6 0.6 (50) 22
95RD28 (father) 55.4 6 2.5 (50) 96
C5RO (normal control) 58.7 6 2.7 (50) –
Microinjection of XPF cDNA
XP126LO uninjected 5.5 6 0.6 (24) 27
XP126LO injected R788W cDNA 12.0 6 0.7 (27) 58
XP126LO injected WT cDNA 22.9 6 0.9 (27) 112
C5RO uninjected 20.6 6 0.5 (29) –
aMean 6 SEM (number of nuclei).
bPercentage of normal.
Figure 1. Cellular responses to UV exposure. (a) Survival assay (semilog
scale); (b) inhibition of DNA synthesis measured 16 h after various doses
of UV (linear scale). All points represent averaged duplicate measurements.
(data not shown). This result assigns the patient to XP group F. Cell
survival studies showed that the relatively low NER activity resulted
in only moderate UV cytotoxicity, much less marked than in XP cells
from group A (Fig 1a). This behavior is characteristic of XP-F as
shown here for XP2YO (Fig 1a) and for other XP-F patients
elsewhere (Arase et al, 1979; Nishigori et al, 1986) (Table II). Also
the consequences for the overall rates of DNA synthesis, measured
16 h after UV exposure, were only moderate: the inhibition was much
less pronounced than in XP-A cells, and similar to an XP-C strain
(Fig 1b), known to be intermediate in this respect. The cells from the
patient’s father showed a normal behavior in the latter two assays (only
DNA synthesis is shown in Fig 1b).
Molecular genetic studies Recently, the XPF gene was cloned
(Sijbers et al, 1996a), which allows mutational analysis of the affected
gene in this patient. Initial restriction enzyme fingerprint analysis by
single-strand conformation-sensitive gel electrophoresis indicated the
presence of specific sequence abnormalities in the downstream end of
cDNA amplified from XP42RO mRNA. These were partly similar
to the ones observed in XP126LO, another XP-F individual (Fig 2a).
XP126LO had been shown earlier to carry a 4nt deletion in one allele,
coding for a truncated protein, 803 aa in length, and a C→T transition
in the other, changing amino acid residue 788 from arginine to
tryptophan (R788W) (Sijbers et al, 1996a). Subsequent sequence
analysis of the region in XP42RO revealed that this patient is
homozygous for the R788W mutation (Fig 2b). Investigation of
genomic DNA verified the homozygous (or hemizygous) state of the
patient and established the father as carrier (Fig 2b). Material from the
mother was not available for analysis.
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Table II. Overview of clinical, photobiologic, and repair characteristics of published XP-F cases
Skin characteristics
Patient description
Acute med/ Freckles Tumors,
Code Sex Age Ref.e erythema peak (AoO) no and type (AoO)f Ocular Neuro %NER UVS
XP23OS F 45 1 1 (6) – no 10 4.3x
XP101OS F 49 2 1d low 1 1 MF (30), 2 BCC, 1 KA no no 15 2x
(47)
XP2YOa F 64 3, 4 1 1 SSC (62), BDC († 65) no 17 3.4x
XP3YOa M 29 3, 4 1 1 KA (26) no 15 2.8x
XP25KO F 8 5, 6 1 low/24 h 1 (1.5) – no no 10–15 3x
XP27KOb F 11 5, 6 1 nor/24 h 1 (3) – no no 10–15 3x
XP28KOb F 8 5, 6 1 1 (3) – no no 10–15 3x
XP41KOb M 5 5, 6 1 1 (3) – no no
XP38KO F 44 6, 7 1 nor/24 h 1 – no no 20–25 2.3x
XP46KO F 61 6 1 nor/24 h 1 (14) – no no 12 2.8x
XP7KA F 42 6, 8 1 nor/24 1 72 h 1 1 BCC (40) no 19
XP90TOc M 42 9 1 nor/48 h 1 (10) 6 BCC (42) 6 no 12 3x
XP92TOc F 41 9 1 nor/48 h 1 (5) 1 BCC (41) no no 12 3x
XP107TO F 73 3 1 low/48 1 72 h 1 (5) 2 BCC, 1 TF (72) no 19 2.3x
Kps6 F 18 10 6 1 (11) 1 BCC (18) no no 20.5 1.3x
MNHN M 48 11 1 (6) 1 BDC († 50) no yes 7 3.1x
XP126LO F 22 12 1 nor/24 h 1 (10) – no no 13





dAfter amoxicilin trihydrate treatment, not after UV.
e1, Arase et al (1979); 2, Nishigori et al (1986); 3, Nishigori et al (1991); 4, Takebe et al (1980); 5, Fujiwara et al (1985b); 6, Yamamura et al (1989); 7, Fujiwara et al (1985a);
8, Arase et al (1988); 9, Kondo et al (1989); 10, Itoh et al (1995); 11, Moriwaki et al (1993); 12, Norris et al (1988).
fAoO, age of onset; BCC, basal cell carcinoma; SCC, sqamous cell carcinoma; KA, keratoacanthoma; TF, trichofolliculoma; MF, mammary fibroadenoma; BDC, bile duct cancer.
Figure 2. Mutational analysis of XP42RO. (a) Restriction enzyme
fingerprint analysis. The restriction enzyme fingerprint is shown of the 39
end of cDNA from normal, XP126LO, and XP42RO cells after digestion
with EaeI, SacI, and StuI. Arrows indicate aberrant bands. (b) Sequence
showing C→T transition in cDNA and genomic DNA. (c) Schematic
structure of XPF protein with R788W mutation. Domains shown in white
are highly conserved; LRM, leucine-rich motif; NLS, putative nuclear
location signal; E1-B, region required for ERCC1 binding. (d) Migration
of XPF (R788W) and normal XPF in vitro translated proteins in a denaturing
gel. Bands smaller than the full-length protein of 115 kDa represent N-
terminally truncated species, caused by translational starts on internal AUG
sites. Aberrant slower mobility of mutated XPF is more readily visible in
the shorter C-terminal products consistent with the mutation being situated
in the C-terminal part of the protein. (e) Immunoblot of equal amounts of
cell-free protein extracts with anti-XPF anti-serum (Sijbers et al, 1996a).
Consequences of the R788W mutation To determine the relev-
ance of the observed change for in vivo NER, an XPF cDNA carrying
the mutation was cloned in a mammalian expression vector with a
strong promoter and microinjected into the nuclei of XP-F strain
XP126LO. This overexpressed XPF species could correct the NER
defect only very partially, whereas the nonmutated cDNA produces
fully normal levels of NER upon microinjection (Table I, bottom panel)
(Sijbers et al, 1996a); however, significant residual activity was evident,
which shows that the R788W substitution is not a null-mutation. On
the protein level, the mutation causes an aberrant electrophoretic
mobility detected in denaturing sodium dodecyl sulfate-polyacrylamide
gel electrophoresis of in vitro translated polypeptides (Fig 2d), indicative
of a considerable conformational change. In XP42RO cell extracts,
the amount of XPF protein is strongly reduced, as measured by
immunoblotting (Fig 2e). The levels were also low in XP126LO but
were intermediate in the father (Fig 2e), in agreement with his
heterozygous state.
DISCUSSION
Patients with a mutated XPF gene are mostly found in Japan, where
it is the most common form of XP after XP-A. Outside Japan, XP-F
is rare. This patient XP42RO represents only the second Caucasian
case ever reported. The first case was an English patient XP126LO
(Norris et al, 1988). Characteristic of XP-F are mild cutaneous
manifestations, relatively late onset of cutaneous carcinomas, and the
absence of neurologic abnormalities. Clinical, photobiologic, and repair
hallmarks of published XP-F cases are summarized in Table II.
Acute sun sensitivity reactions were reported in 14 of 18 patients.
The subnormal MED peak at 24 h in our patient corresponded with
that in seven of 10 other XP-F patients, whereas it was low in only
three. Delayed or morphologically abnormal photosensitivity reactions
have been reported in the majority of XP patients, consistent with the
delayed reaction at 72 h seen in our patient.
Malignant skin tumors first appeared between 27 and 47 y of age,
which is relatively late for XP patients in general, but early among the
nine of 18 XP-F cases where tumors have arisen. The prevalence of
only basal and squamous carcinomas, characteristic for XP-F, is also
lower than in XP-A and XP-D patients. Obviously, tumor risk also
depends on total UV exposure and medical care. Our patient, who
had been extensively exposed to sunlight for at least 12 y, contrasts
with nine tumor-free patients of whom four were still very young
(Table II).
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Residual repair activity is similar to the other XP-F patients. This
4–6 times reduction of overall NER rate seems to be in contradiction
with an only moderate UV cytotoxicity and nucleic acids synthesis
inhibition, a unique feature, typical for the XP-F group, also found in
our patient. This behavior is thought to be caused by a partially
impaired NER activity that proceeds longer and is less reduced at later
times after exposure (Zelle et al, 1980; Arase et al, 1990). The rather
mild cutaneous and ocular manifestations of XP-F are in line with
these repair characteristics.
Whereas the UV-sensitive phenotype of our patient is rather typical
of XP-F, the neurologic abnormalities that started to develop in the
patient’s late forties are unusual and have been reported in only one
exceptional Japanese case so far (Moriwaki et al, 1993), with a type
and onset of neurologic symptoms grossly similar to our case. Five of
the other patients were much younger at the time of report, but in
three aged 50–73 there was no evidence of neurologic problems. In
general, central nervous system dysfunction is not uncommon in XP;
however, usually only cases with the most severe photosensitivity are
affected, such as those in groups A and D (Andrews et al, 1978), where
the problems develop at an early age. Robbins et al (1993) reported
neurologic degeneration in a mildly sensitive XP-C patient who was
in her forties; however, in our case with comparable mild NER
impairment the origin may be distinct and specifically related to the
XPF defect as the course of the neurologic disease was different from
that of the XP-C patient. Peripheral nervous system problems such as
dysmyelination, which are not present in our case, are found in another
repair disorder, Cockayne syndrome, and in rare cases that combine
the features of XP and Cockayne syndrome (Nance and Berry, 1992).
Such patients occur in XP groups B, D, and G only (Hamel et al,
1996; Vermeulen et al, 1997). Therefore, these abnormalities were
proposed to be associated with subtle disturbances in basal transcription,
a process requiring the proper functioning of the XPD and XPB
proteins (Vermeulen et al, 1994b).
The nonstandard clinical picture of our patient prompted us to
perform a more detailed molecular genetic analysis. The assignment to
group F by complementation analysis was confirmed on the molecular
level by the identification of a homozygous mutation in the XPF gene.
A C→T transition (probably due to deamination of a methylated
cytosine at a CpG site) at nucleotide 2377 changes the basic arginine
residue 788 of the encoded protein into a hydrophobic tryptophan.
This mutation is physiologically relevant and most likely responsible
for the patient’s NER defect, because overexpression of microinjected
mutated cDNA cannot fully correct UDS in XP-F cells. Surprisingly,
the same R788W mutation had been found earlier in one of the alleles
of the unrelated English patient XP126LO (Sijbers et al, 1996a). Both
this point mutation and the C-terminal truncation encoded by the
second allele of XP126LO affect the region of the XPF protein that
is required for stable physical interaction with another repair enzyme
called ERCC1 (our unpublished data, see Fig 2c). Uncomplexed, free
XPF and ERCC1 proteins are unstable in vivo (Sijbers et al, 1996b).
Therefore, the strongly reduced levels of XPF protein that we observed
in both patients’ cells (Sijbers et al, 1996a) and the deficiency of XP-
F cells in ERCC1 protein (Biggerstaff et al, 1993; van Vuuren et al,
1995; Yagi et al, 1997) would be readily explained by this interaction
failure; however, in vitro, the R788W protein could still bind ERCC1
(our unpublished data). It follows that the apparent XPF protein
instability in vivo is related to the conformational changes that we
detected in a denaturing gel.
In the process of NER, the XPF-ERCC1 protein complex catalyzes
strand incision at the 59 side of the DNA lesion (Sijbers et al, 1996a;
Bessho et al, 1997). Because this structure-specific endonuclease
activity is essential for reconstitution of NER in vitro (Aboussekhra
et al, 1995; Mu et al, 1995), the presence of significant residual repair
in the XP-F cells suggests that in most patients the mutations are leaky.
Intrinsic residual activity in the R778W mutated protein was apparent
from its capability to partially restore repair in microinjected XP-F
cells that overexpress it.
In conclusion, a homozygous R788W mutation in the XPF gene
underlies the NER defect of patient XP42RO. The mutation causes
strongly reduced but still detectable levels of XPF protein. The
biochemical defect results in clinical and cellular UV responses that
are mild and typical of other XP-F cases reported so far. Whether
the R788W substitution is also responsible for the unusual late-
onset neurologic symptoms in the patient remains to be seen,
because the other European XP-F patient with the same mutation
and showing no neurologic symptoms (Norris et al, 1988) was still
young (22 y) at the time of report. Moreover, extended case finding
and mutational analysis, currently in progress, will also shed
light on the possibility that R788W represents a Caucasian
founder mutation.
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